Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04209621
Title Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Heart, Lung, and Blood Institute (NHLBI)
Age Groups:
Covered Countries USA

Additional content available in CKB BOOST